Imageens

Imageens is a Paris-based company specializing in innovative medical software solutions. Their flagship product, ArtFun+, focuses on enhancing cardiovascular disease prevention through advanced imaging analytics. Founded in 2017 and headquartered in Paris, France, Imageens develops software solutions for cardiologists and healthcare institutions. The company has completed two funding rounds, the latest being a Series A round in February 2021, where they raised EUR 1.

196 mn. The founder, Anas Dogui, has a history in the tech industry and has worked on projects that bridge healthcare and technology. Imageens specializes in advanced medical software solutions, notably its flagship product, ArtFun+. This clinically-validated software as a medical device measures vital MRI imaging biomarkers that indicate cardiovascular diseases.

It aids healthcare professionals in initiating cardiovascular prevention efforts by providing personalized reports assessing cardiovascular age and early disease detection. The software has achieved Class 2a approval under the EU's Medical Device Regulation, allowing marketing across various European countries. End users include cardiologists and medical institutions focused on preventive medicine, leveraging AI-driven insights and large imaging datasets for improved clinical decision-making. Imageens generates revenue through partnerships and direct sales of its software solutions.

The business model is subscription-based, focusing on clinical decision tools that provide analytics and personalized reports to healthcare providers. Revenue fluctuates based on user numbers and institution scale, supported by partnerships with leading healthcare facilities that often include integration services and ongoing support. ArtFun+ is central to these revenue activities, catering to the demand for preventive cardiovascular care solutions. In February 2021, Imageens raised EUR 1.

2 mn in Series A funding, led by individual and unspecified investors. The company will utilize these funds to launch its first two products. Future plans include expanding into new markets and geographic regions, targeting additional European countries by the end of 2023 to enhance its footprint in the preventive cardiovascular care market.